ClinicalTrials.gg
TerminatedNCT03469258Updated Aug 3, 2020Results posted

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

A Phase 2 interventional study of Pancrelipase in Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Supportive care

How we know

Why this study was terminated
Sponsorship for trial was halted after company acquisition

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute — 5 open to participants now, 7 under way, none of them phase 3. Pancreatic Neoplasms · Dana-Farber Cancer Institute.

Enrollment
22nd of 23
4 · median 36
Started
2018
with 4 others
Phase 2
6 of 25
none open now
Registered
13th of 25
by date

Among the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 2, and was the 13th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

5 of the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This research study is evaluating a study drug to treat pancreatic exocrine insufficiency (PEI) during the first year after the diagnosis of pancreatic cancer while the participant is recovering from surgery and receiving adjuvant treatment.

The study drug involved in this study is:

-Zenpep

Read the detailed description

The FDA (the U.S. Food and Drug Administration) has approved Zenpep as a treatment option for PEI. Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.

In this research study, the investigators are studying whether Zenpep will improve the ability of patients to complete adjuvant treatment for their pancreatic cancer after surgery to remove their tumor. The investigators are also studying if Zenpep will have an effect on nutrition status and quality of life for pancreatic cancer patients after they have had surgery to remove their tumor.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed pancreatic ductal adenocarcinoma. Variants or mixed histology will be included if the predominant histology is adenocarcinoma.
  • Participants must have potentially resectable pancreatic cancer defined as: (1) no detectable (2) signed consent for attempted resection of pancreatic cancer per treating surgeon.
  • performance status ≤2.
  • Age >18 years. Participants \<18 years old are excluded from this study because subsequent therapy is based on therapy guidelines in the adult population.
  • Willingness to consider adjuvant therapy following surgical resection of disease, signed in the consent form attestation.
  • Ability to understand and willingness to provide written .
  • Pre-operative laboratory values adequate to undergo resection of pancreatic cancer, as defined below:

    • > 7.0 g/dL;
    • ≥ 40,000/mL;
    • Creatinine \< 2.5 mg/dL or; ≥ 20 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

Exclusion criteria

Exclusion Criteria:

  • Pancreatic resection not performed. Intraoperative findings and unforeseen medical exigent circumstances may preclude pancreatic resection. Such outcomes include undetected or vascular involvement, which preclude resection with intent to cure, as well as perioperative medical events including cardiopulmonary complications.
  • Final pathology other than pancreatic ductal adenocarcinoma or primary component other than adenocarcinoma.
  • Any prior chemotherapy and/or radiation for pancreatic cancer at the time of study enrollment, including chemotherapy and/or radiation therapy.
  • Second with active disease.
  • History of allergic reactions or attributed to compounds of similar chemical or biologic composition to pancrelipase
  • Pregnant women are excluded from this study because subsequent adjuvant therapy needed for the primary endpoint is teratogenic. Pancrelipase is category C. Animal reproduction studies have not been conducted on pancrelipase and minimal data is available.
  • Participants unable to self-administer pancrelipase.
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Participants who are receiving any other agents.
  • Participant unable to tolerate oral nutrition.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Zenpep

    * Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously. * Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date

    Drug: Pancrelipase

Interventions

  • Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.

    Also known as: Zenpep

06

What researchers measure

Primary outcomes

  1. Effect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer

    Completion, or not, of all doses of chemotherapy and fractions of radiation prescribed by the treating oncologist prior to the start of adjuvant treatment

    Time frame: 40 weeks

Secondary outcomes

  1. Initiation Rate of Adjuvant Treatment for Resected Pancreatic Cancer

    Percentage of subjects with resected pancreatic cancer starting adjuvant treatment by postoperative day 84

    Time frame: 84 days after surgery

  2. Subject Adherence to Pancreatic Enzyme Replacement Therapy as Determined by Pill Count

    Pill count performed by study staff to be compared to subject meal and pill diary to determine percent adherence to prescribed regimen

    Time frame: 52 weeks

  3. Subject Adherence to Pancreatic Enzyme Replacement Therapy During Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer

    Pill count performed by study staff will be compared to subject meal and pill diary to determine percent adherence to prescribed regimen

    Time frame: 52 weeks

  4. Measure Serum Albumin Levels Before and After Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer

    Quantify serum albumin (g/dl ) to correlate pancreatic enzyme replacement therapy with nutrition status before and after surgery and adjuvant therapy for early stage pancreatic cancer

    Time frame: 52 weeks

  5. Measure Body Weight Before and After Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer

    Measure body weight (in kg) at regular intervals throughout study participation to investigate whether pancreatic enzyme replacement therapy improves nutrition status during surgery and adjuvant treatment for early stage pancreatic cancer

    Time frame: 52 weeks

  6. Evaluate Quality of Life Before and After Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer Using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire

    Subjects to complete EQ-5D-5L at regular intervals throughout study participation. The scale consists of 5 questions, one each to assess mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has answers ranging from No Problems (level 1) to Extreme Problems (level 5). Subjects also to rate their overall health on a given day using the EuroQoL Visual Analog Scale (EQ-VAS) as a part of the EQ-5D-5L, which consists of marking on a visual scale from 0-100 (with 100 being best imaginable health and 0 being worst health imaginable).

    Time frame: 52 weeks

  7. Monitor the Incidence and Severity of Complications After Surgery for Early Stage Pancreatic Cancer

    Incidence and severity of postoperative complications graded by Clavien-Dindo classification

    Time frame: 84 days after surgery

  8. Measure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer

    Standard grip strength dynamometer measurements at regular intervals throughout the study

    Time frame: 52 weeks

07

Results

Posted Aug 3, 2020
Limitations and caveats
Early termination per sponsor leading to small numbers of subjects enrolled. Those subjects who were enrolled did not meet pathologic criteria to remain on study and would have been replaced had the study continued.

Participant flow

Participant flow — Overall Study
MilestoneZenpep
Started4
Completed0
Not completed4
Withdrew: Upon surgery, did not meet criteria4

Outcome measures

PrimaryEffect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer

Completion, or not, of all doses of chemotherapy and fractions of radiation prescribed by the treating oncologist prior to the start of adjuvant treatment

Time frame:
40 weeks

No measurements were reported for this outcome.

SecondaryInitiation Rate of Adjuvant Treatment for Resected Pancreatic Cancer

Percentage of subjects with resected pancreatic cancer starting adjuvant treatment by postoperative day 84

Time frame:
84 days after surgery

No measurements were reported for this outcome.

SecondarySubject Adherence to Pancreatic Enzyme Replacement Therapy as Determined by Pill Count

Pill count performed by study staff to be compared to subject meal and pill diary to determine percent adherence to prescribed regimen

Time frame:
52 weeks

No measurements were reported for this outcome.

SecondarySubject Adherence to Pancreatic Enzyme Replacement Therapy During Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer

Pill count performed by study staff will be compared to subject meal and pill diary to determine percent adherence to prescribed regimen

Time frame:
52 weeks

No measurements were reported for this outcome.

SecondaryMeasure Serum Albumin Levels Before and After Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer

Quantify serum albumin (g/dl ) to correlate pancreatic enzyme replacement therapy with nutrition status before and after surgery and adjuvant therapy for early stage pancreatic cancer

Time frame:
52 weeks

No measurements were reported for this outcome.

SecondaryMeasure Body Weight Before and After Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer

Measure body weight (in kg) at regular intervals throughout study participation to investigate whether pancreatic enzyme replacement therapy improves nutrition status during surgery and adjuvant treatment for early stage pancreatic cancer

Time frame:
52 weeks

No measurements were reported for this outcome.

SecondaryEvaluate Quality of Life Before and After Surgery and Adjuvant Treatment for Early Stage Pancreatic Cancer Using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire

Subjects to complete EQ-5D-5L at regular intervals throughout study participation. The scale consists of 5 questions, one each to assess mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each question has answers ranging from No Problems (level 1) to Extreme Problems (level 5). Subjects also to rate their overall health on a given day using the EuroQoL Visual Analog Scale (EQ-VAS) as a part of the EQ-5D-5L, which consists of marking on a visual scale from 0-100 (with 100 being best imaginable health and 0 being worst health imaginable).

Time frame:
52 weeks

No measurements were reported for this outcome.

SecondaryMonitor the Incidence and Severity of Complications After Surgery for Early Stage Pancreatic Cancer

Incidence and severity of postoperative complications graded by Clavien-Dindo classification

Time frame:
84 days after surgery

No measurements were reported for this outcome.

SecondaryMeasure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer

Standard grip strength dynamometer measurements at regular intervals throughout the study

Time frame:
52 weeks

No measurements were reported for this outcome.

Adverse events

Collected over 52 weeks after drug initiation and until patient began adjuvant chemotherapy or adjuvant radiation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zenpep0/4 (0%)0/4 (0%)0/4 (0%)

Baseline characteristics

Patients did not meet pathologic criteria upon surgery. Trial was subsequently terminated by sponsor due to company acquisition.

Age, Categorical
Age, CategoricalZenpep
<=18 years—
Between 18 and 65 years—
>=65 years—
Age, Continuous
Age, Continuous(years)Zenpep
Sex: Female, Male
Sex: Female, MaleZenpep
Female—
Male—
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)Zenpep
Hispanic or Latino—
Not Hispanic or Latino—
Unknown or Not Reported—
Race (NIH/OMB)
Race (NIH/OMB)Zenpep
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
Region of Enrollment
Region of Enrollment(participants)Zenpep
Participant must be a candidate for standard of care adjuvant treatment according to their treating
Participant must be a candidate for standard of care adjuvant treatment according to their treatingZenpep
08

Study locations

1 site
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Oct 2019, 17 months.

Results were first posted in Aug 2020, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2018
First posted
Mar 19, 2018
StartActual
Apr 13, 2018
Primary completionActual
Oct 1, 2019
CompletionActual
Oct 1, 2019
Results first posted
Aug 3, 2020
Last update
Aug 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03469258
Collaborators
Allergan
Responsible party
A James Moser (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Mar 19, 2018
Start date
Apr 13, 2018
Primary completion
Oct 1, 2019
Completion
Oct 1, 2019
Results posted
Aug 3, 2020
Last update
Aug 3, 2020

Study contacts

Arthur James Moser, MD
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pancrelipase

Start the discussion